Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
UL
MCID: LMY014
MIFTS: 55

Leiomyoma, Uterine (UL)

Categories: Cancer diseases, Muscle diseases, Nephrological diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Leiomyoma, Uterine

About this section

MalaCards integrated aliases for Leiomyoma, Uterine:

Name: Leiomyoma, Uterine 57 39
Uterine Leiomyoma 12 36 29 54 6
Uterine Fibroids 42 15 62 70
Uterine Fibroid 12 15 17
Plexiform Leiomyoma 12 70
Leiomyoma of Corpus Uteri 12
Uterus Fibroma 12
Ul 57

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
somatic mutation

Miscellaneous:
uterine leiomyomata are found in hereditary leiomyomatosis and renal cell cancer syndrome


HPO:

31
leiomyoma, uterine:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases Nephrological diseases Muscle diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:13223
OMIM® 57 150699
KEGG 36 H01640
ICD9CM 34 218
MeSH 44 D007889
NCIt 50 C3434
SNOMED-CT 67 95315005
ICD10 32 D25
MedGen 41 C0042133
UMLS 70 C0042133 C2242776
Sources

Summaries for Leiomyoma, Uterine

About this section
MedlinePlus : 42 Uterine fibroids are the most common benign tumors in women of childbearing age. Fibroids are made of muscle cells and other tissues that grow in and around the wall of the uterus, or womb. The cause of fibroids is unknown. Risk factors include being African American or being overweight. Many women with fibroids have no symptoms. If you do have symptoms, they may include Heavy or painful periods or bleeding between periods Feeling "full" in the lower abdomen Urinating often Pain during sex Lower back pain Reproductive problems, such as infertility, multiple miscarriages or early labor Your health care provider may find fibroids during a gynecological exam or by using imaging tests. Treatment includes drugs that can slow or stop their growth, or surgery. If you have no symptoms, you may not even need treatment. Many women with fibroids can get pregnant naturally. For those who cannot, infertility treatments may help. NIH: National Institute of Child Health and Human Development

MalaCards based summary : Leiomyoma, Uterine, also known as uterine leiomyoma, is related to kidney cancer and breast disease, and has symptoms including pelvic pain An important gene associated with Leiomyoma, Uterine is MIRLET7C (MicroRNA Let-7c), and among its related pathways/superpathways are MicroRNAs in cancer and Alzheimers Disease. The drugs Leuprolide and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and breast, and related phenotype is uterine leiomyoma.

Disease Ontology : 12 An uterine benign neoplasm derived from the smooth muscle layer of the uterus.

OMIM® : 57 Uterine leiomyoma (UL), commonly known as fibroids, are benign tumors of the uterine myometrium. They represent the most prevalent pelvic tumors in women and are found in more than 75% of women of reproductive age. Approximately 20 to 25% of women with UL exhibit symptoms including menorrhagia, infertility, pelvic pain, and a range of complications during pregnancy. UL are the leading cause for hysterectomy in the United States, accounting for 30% of all hysterectomies (summary by Eggert et al., 2012). (150699) (Updated 05-Apr-2021)

KEGG : 36 Uterine leiomyoma, also known as fibroid, is the most common benign neoplasm of the female genital tract. It is a discrete, round, firm, often multiple uterine tumor composed of smooth muscle and connective tissue. The findings derived from high-throughput sequencing combined with previous knowledge have led to an emerging molecular classification of leiomyomas, suggesting that there are several distinct pathogenic pathways involved in leiomyoma formation. The evidence points to at least 4 molecular subclasses: leiomyomas with MED12 mutation, FH inactivation, HMGA2 overexpression, and COL4A6-COL4A5 deletion. While it is thought that the initial events that trigger leiomyoma tumorigenesis involves somatic mutations, it is evident that the development and growth of leiomyoma are highly dependent on ovarian steroid hormones, in particular, progesterone.

PubMed Health : 62 About uterine fibroids: Many women have benign (non-cancerous) growths known as fibroids in or on their womb (uterus). Most fibroids are small and don't cause any problems. They are usually discovered by chance. Depending on where fibroids are located, they may cause period pain, heavy menstrual bleeding or other symptoms. There are different ways to treat fibroids. The most suitable treatment will greatly depend on a woman’s individual circumstances – such as whether she would still like to have children. Fibroids are made up of muscle cells and connective tissue. Their size, shape and location vary. Fibroids are mainly categorized based on where they are:

Wikipedia : 73 Uterine fibroids, also known as uterine leiomyomas or fibroids, are benign smooth muscle tumors of the... more...

Sources

Related Diseases for Leiomyoma, Uterine

About this section

Diseases related to Leiomyoma, Uterine via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 432)
# Related Disease Score Top Affiliating Genes
1 kidney cancer 30.8 MIR29C MIR27A MIR21 MIR150
2 breast disease 30.4 MIR34A MIR30A MIR27A MIR21 MIR139
3 diffuse large b-cell lymphoma 30.2 MIR27A MIR21 MIR150 MIR139 MIR10A
4 body mass index quantitative trait locus 11 30.2 MIR34A MIR30A MIR27A MIR23B MIR21 MIR144
5 cervical cancer 30.1 MIRLET7C MIR34A MIR23B MIR21 MIR196B
6 esophageal cancer 30.0 MIR34A MIR30A MIR21 MIR203A MIR144 MIR139
7 lymphoma, non-hodgkin, familial 29.8 MIR34A MIR30A MIR27A MIR23B MIR21 MIR144
8 bladder cancer 29.8 MIR34A MIR29C MIR23B MIR21 MIR203A MIR144
9 ovarian cancer 29.6 MIRLET7C MIR542 MIR34A MIR335 MIR30A MIR29C
10 gastric cancer 29.6 MIR34A MIR29C MIR27A MIR21 MIR203A MIR196B
11 renal cell carcinoma, nonpapillary 29.5 MIR34A MIR335 MIR30A MIR29C MIR27A MIR23B
12 gastrointestinal system cancer 29.4 MIR542 MIR34A MIR335 MIR30A MIR29C MIR27A
13 uterine anomalies 29.3 MIR542 MIR34A MIR335 MIR30A MIR29C MIR27A
14 lung cancer 28.8 MIRLET7C MIR542 MIR34A MIR335 MIR32 MIR30A
15 submucous uterine fibroid 11.5
16 subserous uterine fibroid 11.5
17 benign metastasizing leiomyoma 11.2
18 uterine corpus epithelioid leiomyoma 11.1
19 uterine corpus dissecting leiomyoma 11.1
20 uterus interstitial leiomyoma 11.1
21 uterine corpus myxoid leiomyoma 11.1
22 uterine corpus lipoleiomyoma 11.1
23 uterine corpus myxoid leiomyosarcoma 11.1
24 myoma 10.6
25 leiomyomatosis 10.6
26 intravenous leiomyomatosis 10.6
27 adenomyosis 10.5
28 amenorrhea 10.5
29 ovarian serous carcinoma 10.3 MIR27A MIR23B MIR21
30 inclusion body myositis 10.3 MIR34A MIR21 MIR197
31 pleural cancer 10.3 MIR32 MIR29C MIR139
32 intestinal benign neoplasm 10.3 MIR21 MIR139 MIR10A
33 vaginal discharge 10.3
34 infertility 10.3
35 endocrine organ benign neoplasm 10.3 MIR335 MIR21 MIR139
36 laryngeal disease 10.3 MIR34A MIR21 MIR139
37 polymyositis 10.3 MIR34A MIR30A MIR21
38 malignant ovarian surface epithelial-stromal neoplasm 10.3 MIR30A MIR23B MIR21 MIR139
39 gastrointestinal system benign neoplasm 10.3 MIR30A MIR21 MIR139
40 ovary epithelial cancer 10.3 MIR30A MIR23B MIR21 MIR139
41 miyoshi muscular dystrophy 1 10.3 MIR34A MIR335 MIR30A MIR21
42 premature menopause 10.3
43 retinal vascular disease 10.3 MIR30A MIR21 MIR144
44 tongue disease 10.3 MIR30A MIR21 MIR144 MIR139
45 dermatomyositis 10.3 MIR34A MIR335 MIR30A MIR21
46 mesenchymal cell neoplasm 10.3
47 chromosomal triplication 10.3
48 aortic valve disease 2 10.2 MIR34A MIR21 MIR150
49 nemaline myopathy 10.2 MIR34A MIR335 MIR30A MIR29C
50 leukocyte disease 10.2 MIR30A MIR27A MIR21 MIR144

Graphical network of the top 20 diseases related to Leiomyoma, Uterine:



Diseases related to Leiomyoma, Uterine
Sources

Symptoms & Phenotypes for Leiomyoma, Uterine

About this section

Human phenotypes related to Leiomyoma, Uterine:

31
# Description HPO Frequency HPO Source Accession
1 uterine leiomyoma 31 HP:0000131

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Genitourinary Internal Genitalia Female:
uterine leiomyomas, benign

Clinical features from OMIM®:

150699 (Updated 05-Apr-2021)

UMLS symptoms related to Leiomyoma, Uterine:


pelvic pain
Sources

Drugs & Therapeutics for Leiomyoma, Uterine

About this section

PubMed Health treatment related to Leiomyoma, Uterine: 62

Fibroids usually only need to be treated if they are causing fertility problems or could cause problems during pregnancy . The choice of treatment will mainly depend on whether a woman would still like to have children – and how she sees the advantages and disadvantages of the various treatments . The severity of the symptoms and the size and position of the fibroids may also determine which treatments are an option. There is no rush to make a treatment decision. Fibroids usually grow very slowly. So you can take your time to read up on all of the pros and cons of the different treatments . Sometimes it is also a good idea to get several opinions from different doctors. The treatment goals may include the following: Reduce menstrual bleeding Relieve pain, cramps and tension Help with difficulties emptying the bladder and digestion Preserve or improve fertility The treatment options include: Hormone therapies : The main hormone therapies are hormonal contraceptives to reduce heavy menstrual bleeding , and hormones that prevent the production of estrogens (GnRH analogues). Surgical removal of the fibroid or the entire womb . Closing off the blood vessels that supply the fibroid with blood (uterine fibroid embolization). The aim is to shrink the fibroids . Other procedures like focused ultrasound surgery (FUS) . This is a relatively new procedure, and its advantages and disadvantages have not yet been fully studied. FUS uses high-intensity ultrasound waves to heat and destroy the fibroid . Other treatments like painkillers, herbal remedies or acupuncture . NSAID (non-steroidal anti-inflammatory drug) painkillers like ibuprofen or diclofenac have been proven to relieve period pain . But there are no studies that have specifically looked into the effects of NSAIDs in women with fibroids . This is also true for acupuncture . Some herbal remedies have been studied more than others, but there's currently no evidence that they are effective in treating fibroids.

Drugs for Leiomyoma, Uterine (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
2
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
3
Ibuprofen Approved Phase 4 15687-27-1 3672
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
6
Ethanol Approved Phase 4 64-17-5 702
7
Tranexamic Acid Approved Phase 4 1197-18-8 5526
8
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
9
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887 16129715
10
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
11
Ferrous fumarate Approved Phase 4 141-01-5
12
Zinc Approved, Investigational Phase 4 7440-66-6 32051
13
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
14
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
15
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
16
Zinc oxide Approved Phase 4 1314-13-2
17
Calcium carbonate Approved, Investigational Phase 4 471-34-1
18
Tocopherol Approved, Investigational Phase 4 1406-66-2
19
Dydrogesterone Approved, Investigational, Withdrawn Phase 4 152-62-5 9051
20
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
21
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
22
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616
23
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
24
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
25
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
26
Dienogest Approved Phase 4 65928-58-7
27
Goserelin Approved Phase 4 65807-02-5 47725 5311128
28
Desogestrel Approved Phase 4 54024-22-5 40973
29
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
30
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
31
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
32
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
33
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
34
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
35
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
36
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6, 59-43-8 1130
37
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7 5280489
38
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
39
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4 54-47-7 1051
40
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
41
Fibrinolysin Investigational Phase 4 9004-09-5
42
Cobalamin Experimental Phase 4 13408-78-1 6857388
43 Antipyretics Phase 4
44 Anti-Arrhythmia Agents Phase 4
45 Sodium Channel Blockers Phase 4
46 Diuretics, Potassium Sparing Phase 4
47 Pharmaceutical Solutions Phase 4
48 Coagulants Phase 4
49 Hemostatics Phase 4
50 Antifibrinolytic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 226)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of High Intensity Focused Ultrasound Ablation Compared With Myomectomy in Uterine Fibroids:A Randomized Controlled Study Unknown status NCT01239641 Phase 4
2 A Controlled Trial on Uterine Fibroids Treatment Comparing Aromatase Inhibitor Plus GnRH Analogue Versus Ulipristal Acetate Unknown status NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
3 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
4 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
5 Ulipristal Acetate Versus GnRH Analogue for Myometrial Preservation in Patients With Submucosal Uterine Leiomyoma G2 Unknown status NCT02357563 Phase 4 ulipristal acetate;Leuprolide acetate
6 A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
7 A Prospective, Randomized, Single-Center Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
8 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization : a Single-center Prospective Randomized Study Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
9 The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids Completed NCT00995878 Phase 4
10 Understanding Experimentally Induced Hot Flushes and Their Impact on Sleep and Mood Completed NCT00455689 Phase 4 Leuprolide acetate
11 Impact of Experimentally Induced Hot Flashes on Sleep and Mood Disturbance Completed NCT01116401 Phase 4 leuprolide
12 Phase 4 Study of Magnetic Resonance Guided Focused Ultrasound Surgery Following Gonadotrophin Releasing Hormone Agonist Treatment for Symptomatic Uterine Fibroids Completed NCT00159328 Phase 4
13 Efficacy and Safety of Prevadh™ in the Prevention of Adhesions in Gynaecological Surgery: a Multicenter, Randomized, French Study Completed NCT01388907 Phase 4
14 Prospective Randomized Trial of Tranexamic Acid Versus Levonorgestrel Intrauterine System for the Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Completed NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
15 Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids. Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
16 Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Dydrogesterone + Multivitamin Nature in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
17 Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis Recruiting NCT03500367 Phase 4 rapamycin
18 Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Extracts of Plants Pregnenolone & Pyridoxal Phosphate for Treating Uterine Fibroids in Women of Reproductive Age and Women Pregnancy. Active, not recruiting NCT04762316 Phase 4 PP6
19 The Effectiveness and Safety of Ulipristal Acetate in Women With Symptomatic Uterine Fibroid Terminated NCT04132349 Phase 4 Ulipristal Acetate 5 mg
20 Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy in Open, Multicenter Phase IV Clinical Studies Terminated NCT03210324 Phase 4 Mifepristone tablets
21 Magnetic Resonance Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids in Women Desiring Future Pregnancies Terminated NCT00180739 Phase 4
22 A Prospective Randomized Blinded Placebo Controlled Comparison of Multimodal Pre-emptive Analgesia on Long Term Outcome Following Uterine Artery Embolization Terminated NCT01555073 Phase 4 pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group
23 Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin Terminated NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
24 Efficacy and Safety of Pre-operative Vaginal Misoprostol in Reduction of Intraoperative Blood Loss During Myomectomy. Amulticentre Single Blind Randomized Trial. Unknown status NCT03509168 Phase 2, Phase 3 Misoprostol Pfizer Brand
25 Single Blinded Randomized Study of Volume Reduction of Uterine Fibroids After Uterine Artery Embolization Versus Computer Tomography or Ultrasound Guided Percutaneous Microwave Ablation Evaluated by Magnetic Resonance Imaging Unknown status NCT02942537 Phase 2, Phase 3
26 Multi-Center Clinical Trial of Uterine Artery Embolization Treatment of Uterine Leiomyoma Unknown status NCT00821275 Phase 2, Phase 3
27 Placebo-controlled,Doubled,Randomized Trial Evaluating the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women Undergoing Laparoscopic Myomectomy Completed NCT01715597 Phase 3 ascorbic acid;Normal saline
28 A Clinical Study To Evaluate the Safety and Efficacy of MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication Techniques Completed NCT00365989 Phase 3
29 Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner Completed NCT01064960 Phase 3
30 Therapeutic MRI Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids Completed NCT01141062 Phase 3
31 A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of 3-months Open-label Treatment With PGL4001, Followed by a Randomised, Double-blind Placebo Controlled Period of 10 Days Treatment With Progestin, in Subjects With Myomas and Heavy Uterine Bleeding. Completed NCT01156857 Phase 3 PGL4001, placebo;PGL4001, progestin
32 A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of Three Successive Periods of 3-month Open-label PGL4001 Treatment, Each Followed by Ten Days of Double-blind Treatment With Progestin or Placebo and a Drug-free Period Until Return of Menses, in Subjects With Myomas and Heavy Uterine Bleeding Completed NCT01252069 Phase 3 PGL4001, placebo, drug free period;PGL4001, progestin, drug free period
33 MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Clinical Study to Validate the Changes to ExAblate 2000 Device Completed NCT00295217 Phase 3
34 A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of OBE2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT03070951 Phase 3 OBE2109;Placebo to match OBE2109;Placebo to match Add-back;Add-back
35 A Phase III, Multicentre, Randomized, Double-blind Clinical Study, Investigating the Efficacy and Safety of Repeated 12-week Courses of Daily 5mg or 10mg Doses of PGL4001 for the Long-term Management of Symptomatic Uterine Fibroids Completed NCT01629563 Phase 3 PGL4001 5 mg;PGL4001 10 mg
36 A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT02691494 Phase 3 Elagolix;Placebo for Estradiol/Norethindrone Acetate;Estradiol/Norethindrone Acetate;Placebo for Elagolix
37 A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT02654054 Phase 3 Elagolix;Placebo for Estradiol/Norethindrone Acetate;Estradiol/Norethindrone Acetate;Placebo for Elagolix
38 A Phase III, Multicentre, Extension Study Investigating the Efficacy and Safety of Repeated Intermittent 3-month Courses of Open-label Administration of Ulipristal Acetate, in Subjects With Symptomatic Uterine Myomas and Heavy Uterine Bleeding Completed NCT01642472 Phase 3 Ulipristal Acetate - open label
39 Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Completed NCT02925494 Phase 3 Estradiol/Norethindrone Acetate;Elagolix
40 Mifepristone 5 mg Versus 10 mg During 6 Months for the Treatment of Uterine Leiomyomata. A Randomized, Double Blinded Clinical Trial. Completed NCT00886873 Phase 2, Phase 3 Mifepristone
41 Mifepristone 5 mg Versus 10 mg for the Treatment of Uterine Leiomyomata. A Randomized, Double Blinded Clinical Trial. Completed NCT00712595 Phase 2, Phase 3 Mifepristone;Mifepristone
42 A Multicenter, Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids Completed NCT02655237 Phase 3 Relugolix;Relugolix Placebo;Leuprorelin;Leuprorelin Placebo
43 A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids Completed NCT02655224 Phase 3 Relugolix;Relugolix placebo
44 LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Completed NCT03049735 Phase 3 Relugolix;Estradiol/norethindrone acetate;Estradiol/norethindrone acetate placebo;Relugolix placebo
45 EMMY Trial: a Randomized Comparison of Uterine Artery Embolization and Hysterectomy for the Treatment of Symptomatic Uterine Fibroids Completed NCT00100191 Phase 3
46 LIBERTY 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Completed NCT03103087 Phase 3 Relugolix;Estradiol/norethindrone acetate;Relugolix placebo;Estradiol/norethindrone acetate placebo
47 LIBERTY EXTENSION: An International Phase 3 Open-Label, Single-Arm, Long-Term Efficacy and Safety Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Completed NCT03412890 Phase 3 Relugolix;Estradiol/norethindrone acetate
48 A Double-blind, Randomized, Two-dose Trial of Tumor-shrinking Decoction (TSD), a Chinese Medicine Preparation in Patients With Symptomatic Uterine Fibroids Completed NCT02189083 Phase 3 TSD
49 Multicenter, Randomized Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids (MRgFUS TUF) Compared to Myomectomy in Symptomatic Medication and Not Sufficiently Treatable Uterine Fibroids Recruiting NCT03948789 Phase 3
50 Evaluation the Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Patients Recruiting NCT03134157 Phase 3 oral drug and vaginal placebo;oral drug and oral placebo;Vaginal placebo+ oral placebo

Search NIH Clinical Center for Leiomyoma, Uterine

Sources

Genetic Tests for Leiomyoma, Uterine

About this section

Genetic tests related to Leiomyoma, Uterine:

# Genetic test Affiliating Genes
1 Uterine Leiomyoma 29
Sources

Anatomical Context for Leiomyoma, Uterine

About this section

MalaCards organs/tissues related to Leiomyoma, Uterine:

40
Uterus, Smooth Muscle, Breast, Lung, Bone, Endothelial, Prostate
Sources

Publications for Leiomyoma, Uterine

About this section

Articles related to Leiomyoma, Uterine:

(show top 50) (show all 2327)
# Title Authors PMID Year
1
Involvement of fumarate hydratase in nonsyndromic uterine leiomyomas: genetic linkage analysis and FISH studies. 54 57
15334541 2004
2
Allelotype of uterine leiomyomas. 57 61
10549262 1999
3
Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas. 57 54
9892177 1999
4
Comparative messenger ribonucleic acid analysis of immediate early genes and sex steroid receptors in human leiomyoma and healthy myometrium. 57 54
9253340 1997
5
Involvement of the long arm of chromosome 12 in chromosome rearrangements of uterine leiomyoma. 57 61
3355999 1988
6
Clinical indications for total abdominal hysterectomy among women seen in Dar es Salaam regional referral hospitals, Tanzania: a prospective, observational hospital-based study. 42 61
33520079 2021
7
Genome-wide linkage and association analyses implicate FASN in predisposition to Uterine Leiomyomata. 57
23040493 2012
8
MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. 57
21868628 2011
9
A genome-wide association study identifies three loci associated with susceptibility to uterine fibroids. 57
21460842 2011
10
Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele. 57
19132395 2009
11
Differential expression of microRNA species in human uterine leiomyoma versus normal myometrium. 61 47
17765232 2008
12
Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. 47 61
18403645 2008
13
A specific translocation, t(12;14)(q14-15;q23-24), characterizes a subgroup of uterine leiomyomas. 57
3355995 1988
14
Clinical significance of performing Sonazoid-based contrast-enhanced ultrasonography before ablation of uterine fibroids by high-intensity focused ultrasound: A preliminary cohort study. 42
33466163 2021
15
Blood loss from transverse versus longitudinal uterine incision in abdominal myomectomy: a randomized controlled trial. 42
33357218 2020
16
Dietary glycemic index and load in relation to risk of uterine leiomyomata in the Black Women's Health Study. 61 54
20200259 2010
17
Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. 61 54
20414849 2010
18
The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. 54 61
20056218 2010
19
Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. 54 61
20124487 2010
20
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. 61 54
19135657 2010
21
Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. 61 54
19700613 2009
22
A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. 61 54
19734847 2009
23
Ascites in puerperium: a rare case of atypical pseudo-Meigs' syndrome complicating the puerperium. 54 61
19322576 2009
24
No association between estrogen receptor beta polymorphisms and uterine leiomyoma. 61 54
19715484 2009
25
Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells. 54 61
19808856 2009
26
Catechol-o-methyltransferase expression and 2-methoxyestradiol affect microtubule dynamics and modify steroid receptor signaling in leiomyoma cells. 61 54
19809499 2009
27
Dual actions of progesterone on uterine leiomyoma correlate with the ratio of progesterone receptor A:B. 54 61
19499404 2009
28
Uterine leiomyomata in relation to insulin-like growth factor-I, insulin, and diabetes. 61 54
19305350 2009
29
Pulmonary benign metastasizing leiomyoma in a postmenopausal woman. 54 61
19506459 2009
30
High aromatase expression in uterine leiomyoma tissues of African-American women. 54 61
19240151 2009
31
Sex hormone binding globulin and aging. 54 61
18956301 2009
32
Downregulation of SRF-FOS-JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas. 61 54
19151755 2009
33
Sex steroidal modulation of collagen metabolism in uterine leiomyomas. 61 54
19400409 2009
34
Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. 61 54
18249392 2009
35
Development of an early biomarker for the ovarian liability of selective estrogen receptor modulators in rats. 54 61
18824103 2008
36
The expression of estrogen receptor isoforms alpha, beta and insulin-like growth factor-I in uterine leiomyoma. 61 54
19012097 2008
37
Combined differential gene expression profile and pathway enrichment analyses to elucidate the molecular mechanisms of uterine leiomyoma after gonadotropin-releasing hormone treatment. 61 54
18258233 2008
38
Potential link between estrogen receptor-alpha gene hypomethylation and uterine fibroid formation. 61 54
18701604 2008
39
Labial aggressive angiomyxoma associated with endometrial hyperplasia and uterine leiomyoma: a case report and review of the literature. 54 61
18839858 2008
40
Association of the CYP17 gene polymorphism with risk for uterine leiomyoma in Brazilian women. 61 54
18645709 2008
41
Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. 61 54
18231572 2008
42
Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. 54 61
18281245 2008
43
Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. 61 54
18216291 2008
44
CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma. 61 54
18182446 2008
45
Association study between catechol-O-methyltransferase polymorphisms and uterine leiomyomas in a Japanese population. 61 54
18390078 2008
46
Polymorphisms of CYP17A1, CYP19, and androgen in Brazilian women with uterine leiomyomas. 61 54
18601603 2008
47
Action of progesterone receptor modulators on uterine leiomyomas. 61 54
18754282 2008
48
Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells. 61 54
18272045 2008
49
Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells. 61 54
17785366 2007
50
Early growth response gene-1 plays a pivotal role in down-regulation of a cohort of genes in uterine leiomyoma. 61 54
17975260 2007
Sources

Variations for Leiomyoma, Uterine

About this section

ClinVar genetic disease variations for Leiomyoma, Uterine:

6 (show all 31)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FH NM_000143.3(FH):c.322C>T (p.Gln108Ter) SNV Likely pathogenic 393560 rs1060499630 GRCh37: 1:241676959-241676959
GRCh38: 1:241513659-241513659
2 PTCH1 NM_001083602.2(PTCH1):c.-241del Deletion Uncertain significance 523402 rs1554710890 GRCh37: 9:98278994-98278994
GRCh38: 9:95516712-95516712
3 HMGA2 NM_003483.4(HMGA2):c.283-2A>G SNV Uncertain significance 800987 rs1592471112 GRCh37: 12:66357023-66357023
GRCh38: 12:65963243-65963243
4 MED12 NM_005120.3(MED12):c.131G>A (p.Gly44Asp) SNV not provided 92220 rs199469672 GRCh37: X:70339254-70339254
GRCh38: X:71119404-71119404
5 MED12 NM_005120.3(MED12):c.100-1_139del Deletion not provided 92197 rs199469676 GRCh37: X:70339221-70339261
GRCh38: X:71119371-71119411
6 MED12 NM_005120.3(MED12):c.100_141del (p.Asp34_Asn47del) Deletion not provided 92198 rs199469677 GRCh37: X:70339223-70339264
GRCh38: X:71119373-71119414
7 MED12 NM_005120.3(MED12):c.100-8T>A SNV not provided 92199 rs199469675 GRCh37: X:70339215-70339215
GRCh38: X:71119365-71119365
8 MED12 NM_005120.3(MED12):c.103_138del (p.Glu35_Asn46del) Deletion not provided 92200 rs199469678 GRCh37: X:70339224-70339259
GRCh38: X:71119374-71119409
9 MED12 NM_005120.3(MED12):c.107T>G (p.Leu36Arg) SNV not provided 92201 rs199469667 GRCh37: X:70339230-70339230
GRCh38: X:71119380-71119380
10 MED12 NM_005120.3(MED12):c.107_111delinsGC (p.Leu36_Thr37delinsArg) Indel not provided 92202 rs199469679 GRCh37: X:70339230-70339234
GRCh38: X:71119380-71119384
11 MED12 NM_005120.3(MED12):c.111_155del (p.Ala38_Ser52del) Deletion not provided 92203 rs199469681 GRCh37: X:70339233-70339277
GRCh38: X:71119383-71119427
12 MED12 NM_005120.3(MED12):c.113_121del (p.Ala38_Asn40del) Deletion not provided 92204 rs199469682 GRCh37: X:70339235-70339243
GRCh38: X:71119385-71119393
13 MED12 NM_005120.3(MED12):c.117_122del (p.Asn40_Val41del) Deletion not provided 92205 rs199469683 GRCh37: X:70339239-70339244
GRCh38: X:71119389-71119394
14 MED12 NM_005120.3(MED12):c.118_132del (p.Asn40_Gly44del) Deletion not provided 92206 rs199469684 GRCh37: X:70339241-70339255
GRCh38: X:71119391-71119405
15 MED12 NM_005120.3(MED12):c.118_134delinsTA (p.Asn40_Phe45delinsTyr) Indel not provided 92207 rs199469680 GRCh37: X:70339241-70339257
GRCh38: X:71119391-71119407
16 MED12 NM_005120.3(MED12):c.118_146delinsTT (p.Asn40_Pro49delinsPhe) Indel not provided 92208 rs199469685 GRCh37: X:70339241-70339269
GRCh38: X:71119391-71119419
17 MED12 NM_005120.3(MED12):c.122_148del (p.Val41_Pro49del) Deletion not provided 92209 rs199469686 GRCh37: X:70339243-70339269
GRCh38: X:71119393-71119419
18 MED12 NM_005120.3(MED12):c.122_163del (p.Val41_Asp54del) Deletion not provided 92210 rs199469687 GRCh37: X:70339242-70339283
GRCh38: X:71119392-71119433
19 MED12 NM_005120.3(MED12):c.123_152del (p.Lys42_Val51del) Deletion not provided 92211 rs199469688 GRCh37: X:70339243-70339272
GRCh38: X:71119393-71119422
20 MED12 NM_005120.3(MED12):c.126_131del (p.Lys42_Gly44delinsAsn) Deletion not provided 92212 rs199469689 GRCh37: X:70339249-70339254
GRCh38: X:71119399-71119404
21 MED12 NM_005120.3(MED12):c.126_140del (p.Lys42_Asn46del) Deletion not provided 92213 rs199469690 GRCh37: X:70339247-70339261
GRCh38: X:71119397-71119411
22 MED12 NM_005120.3(MED12):c.128A>C (p.Gln43Pro) SNV not provided 92214 rs199469668 GRCh37: X:70339251-70339251
GRCh38: X:71119401-71119401
23 MED12 NM_005120.3(MED12):c.129_137del (p.Gln43_Asn46delinsHis) Deletion not provided 92215 rs199469691 GRCh37: X:70339251-70339259
GRCh38: X:71119401-71119409
24 MED12 NM_005120.3(MED12):c.129_143del (p.Gly44_Gln48del) Deletion not provided 92216 rs199469692 GRCh37: X:70339250-70339264
GRCh38: X:71119400-71119414
25 MED12 NM_005120.3(MED12):c.130G>A (p.Gly44Ser) SNV not provided 92217 rs199469669 GRCh37: X:70339253-70339253
GRCh38: X:71119403-71119403
26 MED12 NM_005120.3(MED12):c.130G>C (p.Gly44Arg) SNV not provided 92218 rs199469669 GRCh37: X:70339253-70339253
GRCh38: X:71119403-71119403
27 MED12 NM_005120.3(MED12):c.130G>T (p.Gly44Cys) SNV not provided 92219 rs199469669 GRCh37: X:70339253-70339253
GRCh38: X:71119403-71119403
28 MED12 NM_005120.3(MED12):c.131G>C (p.Gly44Ala) SNV not provided 92221 rs199469672 GRCh37: X:70339254-70339254
GRCh38: X:71119404-71119404
29 MED12 NM_005120.3(MED12):c.131G>T (p.Gly44Val) SNV not provided 92222 rs199469672 GRCh37: X:70339254-70339254
GRCh38: X:71119404-71119404
30 MED12 NM_005120.3(MED12):c.133_144del (p.Phe45_Gln48del) Deletion not provided 92223 rs199469693 GRCh37: X:70339256-70339267
GRCh38: X:71119406-71119417
31 MED12 NM_005120.3(MED12):c.149_163del (p.Ala50_Asp54del) Deletion not provided 92224 rs199469694 GRCh37: X:70339270-70339284
GRCh38: X:71119420-71119434

Copy number variations for Leiomyoma, Uterine from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 70739 12 64503703 64646338 Duplication HMGA2 Uterine leiomyoma
2 230938 8 100959547 100975071 Translate COX6C Uterine leiomyoma
Sources

Expression for Leiomyoma, Uterine

About this section
Search GEO for disease gene expression data for Leiomyoma, Uterine.
Sources

Pathways for Leiomyoma, Uterine

About this section

Pathways related to Leiomyoma, Uterine according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MicroRNAs in cancer 36
11.89 MIRLET7C MIR34A MIR335 MIR32 MIR30A MIR29C
2
Alzheimers Disease 1
11.63 MIR10A MIR139 MIR21 MIR323A
3
Parkinsons Disease Pathway 1
11.36 MIR30A MIR212 MIR10A
4
miRNAs involved in DNA damage response 1
10.96 MIR542 MIR27A MIR23B MIR203A
5
Metastatic brain tumor 1
10.77 MIRLET7C MIR29C
Sources

GO Terms for Leiomyoma, Uterine

About this section

Cellular components related to Leiomyoma, Uterine according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 9.5 MIRLET7C MIR34A MIR30A MIR29C MIR27A MIR23B
2 extracellular space GO:0005615 9.47 MIRLET7C MIR335 MIR323A MIR30A MIR29C MIR27A

Biological processes related to Leiomyoma, Uterine according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.85 MIR34A MIR23B MIR212 MIR21 MIR144
2 negative regulation of angiogenesis GO:0016525 9.77 MIR34A MIR29C MIR212 MIR21 MIR10A
3 negative regulation of cell migration GO:0030336 9.74 MIR34A MIR29C MIR21
4 transforming growth factor beta receptor signaling pathway GO:0007179 9.65 MIR30A MIR212 MIR21
5 miRNA mediated inhibition of translation GO:0035278 9.65 MIR29C MIR27A MIR212 MIR21 MIR144
6 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.62 MIR27A MIR23B MIR150 MIR10A
7 gene silencing by miRNA GO:0035195 9.62 MIRLET7C MIR542 MIR376B MIR34A MIR335 MIR323A
8 negative regulation of vascular endothelial cell proliferation GO:1905563 9.58 MIR34A MIR29C
9 positive regulation of vascular endothelial cell proliferation GO:1905564 9.56 MIR27A MIR21
10 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.55 MIR34A MIR21
11 negative regulation of amyloid precursor protein biosynthetic process GO:0042985 9.54 MIR323A MIR144
12 negative regulation of cholesterol efflux GO:0090370 9.52 MIR27A MIR144
13 positive regulation of cellular senescence GO:2000774 9.51 MIR34A MIR10A
14 negative regulation of gene expression GO:0010629 9.5 MIR34A MIR29C MIR27A MIR23B MIR212 MIR21
15 positive regulation of endothelial cell differentiation GO:0045603 9.49 MIR21 MIR150
16 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.46 MIR27A MIR23B MIR21 MIR10A
17 negative regulation of cell cycle G1/S phase transition GO:1902807 9.43 MIR29C MIR10A
18 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.4 MIR27A MIR21

Molecular functions related to Leiomyoma, Uterine according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.61 MIR34A MIR323A MIR30A MIR29C MIR27A MIR23B
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.5 MIRLET7C MIR34A MIR323A MIR32 MIR30A MIR29C
Sources

Sources for Leiomyoma, Uterine

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....